View article

Sahil Khanna, GA Hecht, Erik Dubberke, Robert Orenstein, Christine Lee, DN Gerding

2017/5/6

Digestive Diseases

2017

Alterations in Microbial Diversity are Associated with Treatment Success with RBX2660, a Microbiota-Based Drug for the Preventio Page 1 ©2015 MFMER | slide-1 Alterations in Microbial Diversity are Associated with Treatment Success with RBX2660, a Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection: Results from PUNCH CD 2: a Randomized Double-Blind Placebo-Controlled Trial Sahil Khanna, Gail Hecht, Erik Dubberke, Robert Orenstein, Christine Lee and Dale Gerding. Digestive Diseases Week 2017 May 6th, 2017 Page 2 ©2015 MFMER | slide-2 Disclosures • Research support • Rebiotix, Inc • Merck • Consulting • Assembly biosciences • Rebiotix, Inc (paid to institution) Page 3 ©2015 MFMER | slide-3 Recurrent C. difficile is a Difficult Problem • ~83,000 cases of recurrent C. difficile infection (CDI) in the US every year • Difficult to treat with antibiotics for CDI • ~60% risk after …